Market Size (2015)
2015
$3.90B
Healthcare
Immunoassays in R D Market
By Segment, By Region, And Segment Forecasts, 2015 – 2023
Vertical: HealthcareBase Year: 201712 Sections
Executive Summary
Immunoassays in R D Market — Snapshot
Projected (2023)
2023
$7.72B
CAGR (2015–2023)
8.9%
8.9%Key Players
108+
The factors such as increasing demand for immunoassays in different sectors, and technological advancement for immunoassays in R&D are boosting the growth of the market. In addition, untapped emerging economies are propelling the growth of the market. The shortage of skilled professionals is providing significant growth opportunities for the market.
Key Insight
The Immunoassays in R D Market market is projected to grow at a CAGR of 8.9% from 2015 to 2023.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: Middle East and Africa, Americas, Asia Pacific, Europe.
- Market Segmentation: The market is analyzed across 3 segments: Kits and Reagents, Analyzers, Software and Services. Forecasts are provided for each segment from 2015 to 2023.
- Competitive Landscape: 108 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
Immunoassays in R D Market — Growth Trajectory
Immunoassays are a bioanalytical procedure, in which the quantitation of the analyte depends upon the reaction of an antigen (analyte) and an antibody. Immunoassays have been extensively used in many areas of pharmaceutical analysis such as diagnosis of diseases, therapeutic drug monitoring, and clinical pharmacokinetics and bioequivalence studies in drug discoveries.
Immunoassays in R D Market — Growth Trajectory
Kits and Reagents
Analyzers
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Product & Services Product & Services is broken down into: Kits and Reagents, Analyzers, Software and Services.
- Type Type is broken down into: ELISA, Enzyme-Linked Immunospot Assay (ELISpot), RadioImmunoassay (RIA), Chemiluminescence (CLIA), Fluoroimmnoassay, Others.
- Application Application is broken down into: Infectious Diseases, Cancer Research, Endocrinology, Autoimmune Diseases, Application_Others.
- End User End User is broken down into: Pharmaceutical and Biotechnology Companies, Academic Institutions and Laboratories, End User_Others.
Geographic Analysis
Regional market breakdown
- Middle East and Africa Middle East and Africa market size reached $306.50M in 2015 and is projected to reach $570.40M by 2023, growing at a CAGR of 8.1%.
- Americas Americas market size reached $1.50B in 2015 and is projected to reach $3.04B by 2023, growing at a CAGR of 9.2%.
- Asia Pacific Asia Pacific market size reached $835.40M in 2015 and is projected to reach $1.70B by 2023, growing at a CAGR of 9.3%.
- Europe Europe market size reached $1.25B in 2015 and is projected to reach $2.42B by 2023, growing at a CAGR of 8.5%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
Immunoassays in R D Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Research Process
Historical data (2015–2017) and forecast period (2017–2023)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
Immunoassays in R D Market — Competitive Analysis
Threat of New Entrants
The threat of new entrants in the global Immunoassays in R&D market is moderate. The global Immunoassays in R&D market is steadily growing, hence attracting many new entrants who are looking to make a profit. However, the entry barriers are high due to strict government norms and regulations which decreases the threat of new entrants to some level. Companies aim to increase their market share and capture the market share which is mostly untouched by major players. Hence, the threat of new entrants in the global Immunoassays in R&D market is expected to be moderate.
Bargaining Power of Suppliers
The bargaining power of suppliers in the global Immunoassays in R&D market is high as there is an increase in demand for raw materials by pharmaceutical companies. However, the number of suppliers is also high in the market, which is slightly decreasing the bargaining power of suppliers due to low switching costs. Additionally, the supply of raw materials is disrupted to some level due to the logistics issues that the world is facing currently, which in turn increases the bargaining power of suppliers.
Threat of Substitutes
The threat of substitutes in the Immunoassays in R&D market is low. Immunoassays as a whole do not have substitutes and are essential in diagnosis and R&D. They are essential in studying the binding between specific antigens and antibodies. However, there is an internal substitution in the market among products offered by different players. There are several players offering similar products at competitive prices, which increases the threat of substitutes between players.
Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global Immunoassays in R&D market. There are a high number of players providing immunoassays at similar prices, however, test accuracy is key and only a few players provide high quality immunoassay products to be used in R&D. Hence, this lowers the bargaining power of buyers to some extent.
Intensity of Rivalry
The degree of competition in the Immunoassays in R&D market is high owing to the presence of a large number of prominent players. The low level of product differentiation among existing players increases the intensity of rivalry in the market. Key players are trying to develop economical and more accurate products to make their offerings more affordable and attractive. Such innovations might increase the level of product differentiation and will support the sales of the manufacturers.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for Immunoassays in R D Market.
Regional Market Size (USD Mn)
Market estimates by geography (2023)
USD Mn
InsightAmericas leads with $3.04B by 2023, while Asia Pacific is projected to grow fastest at a 9.3% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $306.50M | $447.60M | $570.40M | 8.1% | 7% |
| Americas | $1.50B | $2.22B | $3.04B | 9.2% | 39% |
| Asia Pacific | $835.40M | $1.17B | $1.70B | 9.3% | 22% |
| Europe | $1.25B | $1.85B | $2.42B | 8.5% | 31% |
| Total | $3.90B | $5.69B | $7.72B | 8.9% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2023)
Kits and Reagents
Analyzers
Software and Services
01014202730414054
Segment Market Share
- Kits and Reagents48%
- Analyzers31%
- Software and Services21%
Total Market Size
$7.72B
Market by Segment (2023)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Kits and Reagents | $3.69B | 8.9% | 88% |
| Analyzers | $2.38B | 8.9% | 60% |
| Software and Services | $1.65B | 8.9% | 81% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
Immunoassays in R D Market — Key Findings
Analytical insights on Immunoassays in R D Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The Immunoassays in R D Market market is projected to reach $7.72B by 2023, growing at 8.9% CAGR. The Kits and Reagents segment holds the largest share.
Market Dynamics
Increasing demand for immunoassays in different sectors and technological advancements are major factors driving the growth of the global immunoassays R&D market. However, the shortage of skilled professionals is expected to hamper the growth of the global market. Nevertheless, it is anticipated that the untapped emerging economies will create lucrative opportunities for the players operating in the global market.
Market Drivers
The demand for immunoassays in different sectors including the pharmaceutical & biopharmaceutical industries, contract research organizations, and academic institutes has rapidly increased in research and development processes which, in turn, has positively contributed to the market growth. Immunoassays have numerous applications in drug and vaccine development. The growing demand for small molecule drugs, innovative biologics, and regenerative pharmaceuticals & biopharmaceuticals drives up the demand for immunoassays in the pharmaceutical and biotechnology industries. Furthermore, ongoing trends such as increasing approvals of novel therapeutics and rising investments in cell & gene therapy is further bolstering the market growth.
Moreover, the demand for precision medicine is increasing owing to the rising prevalence of chronic diseases such as cancer, heart disease, and diabetes. As per the American Cancer Society, various types of cancer including colorectal cancer, breast cancer, lung cancer, certain types of leukemia, lymphoma, and melanoma has fuelled the demand for precision medicine. According to the World Cancer Research Fund International, colorectal cancer is the third most common cancer worldwide and accounted for 1.9 million new cases of colorectal cancer in 2020. It is the third most common cancer in men and the second most common cancer in women.
Hence, the growing demand for biologics, rapid approvals of novel therapeutics, increasing demand for precision medicine, and rising prevalence of cancer has boosted the adoption of immunoassays in R&D.
Market Opportunities
Emerging economies such as India, China, and France are experiencing lucrative growth opportunities due to the increasing population and the rising geriatric population. The huge population pool, a lack of awareness about health, the development of new diseases that require further research for drug development, and the rising incidences of chronic illnesses According to the Department of Economic and Social Affairs' World Population Prospects 2022, population growth by 2100 is expected to be 10.4 billion. The rising prevalence of communicable diseases such as COVID-19, dengue, hepatitis, measles, and the human immunodeficiency virus is propelling the adoption of immunoassays in R&D thereby aiding market growth.
As per the Joint United Nations Programme on HIV/AIDS (UNAIDS), there were 1.5 million newly infected people with HIV across the globe in 2021. Moreover, 38.4 million people were living with HIV in 2021. In addition, the high incidence of non-communicable diseases, including chronic lung disease, heart disease, stroke, cancer, and diabetes is positively contributing to the market growth. As per the World Health Organization, chronic obstructive pulmonary disease (COPD) was the third leading cause of death and accounted for 3.23 million deaths in 2019. As a result, rising population and communicable & noncommunicable disease incidences is driving the drug discovery and development and is anticipated to bolster the market growth in the coming years.
Market Restraints
The immunoassay market in R&D has been stifled due to a scarcity of skilled professionals. The rising requirement for drug discovery and development owing to increases in lifestyle changes and communicable and non-communicable diseases further requires advanced instruments to speed up the development of drugs and vaccines. Moreover, the pharmaceutical and biopharmaceutical industries are giving preference to intelligent automation, decentralization of clinical trials, and precision medicine, which further require a skilled workforce to run advanced technology.
The rising demand for advanced instruments further increases the demand for skilled professionals. Healthcare advancements coupled with high adoption of digital technologies have transformed the life sciences industries. Moreover, life science industries are currently competing with the IT and communications sectors for skilled engineers to work on new vaccines, precision medicine, and repurposed drugs. As a result, it is estimated that a talented workforce will be required during the forecast period in order to eliminate errors and provide high-quality results.
Strategic Outlook and Future Directions
The COVID-19 pandemic has significantly and positively impacted the global immunoassays in R&D market. During the pandemic immunoassays were extensively utilized to test for COVID-19. Immunoassays were used to detect the levels of antibodies for SARS-CoV-2 in human serum. Due to the pandemic, extensive R&D efforts were undertaken in order to develop accurate diagnostic products to test for COVID-19 which can be produced at mass, along with development of novel vaccines and drugs to counter the rising number of cases and effects of the virus. Additionally, immunoassays are employed in the production of vaccines to evaluate the titer, purity, affinity, potency, and immunogenic response of the vaccines in both animals and people. This had a positive impact on the market, significantly driving market growth.
The pandemic has impacted the business environment for several organizations worldwide. The supply chain in the global immunoassays in R&D market is the key to fulfilling customer demands. In addition, due to the pandemic, several countries have imposed import and export limitations. This has also affected the healthcare industry as many countries are dependent on other countries for raw material supply and technology transfer. However, regulatory bodies took significant initiatives to ensure efficient supply chain management during the pandemic. Additionally, for immunoassays targeted at COVID-19 testing, there was a shortage of the same as demand for such kits and reagents had skyrocketed, while the production rate and laboratory testing capacities could not cope-up. To overcome such challenges, key players also expanded their manufacturing capabilities to meet demand. For instance, in July 2020, Becton, Dickinson and Company (BC) (US) received USD 24 million investment by the US government to ramp up manufacturing for its BD Veritor SARS-CoV-2 immunoassay tests to cater to global demand. Such initiatives aided in strengthening the supply chain. Similarly, in November 2022, Bio-Techne Corporation (US) also announced its opening of a 52,000 square foot immunoassay manufacturing facility in the US. Hence, the pandemic had moderately impacted the global immunoassays in R&D market.
The COVID-19 pandemic had positively impacted on players operating in the market. This is especially due to the new wave of demand and interest that has come into immunoassays and its applications in COIVD-19 research & vaccines development, and its diagnosis. Players such as BD (US), Roche (Switzerland) and Abbott (US) reported significant increase in sales of its immunoassay products owing to the pandemic. However, as the effects of the pandemic started to diminish, number of cases decline, and majority of the populations got vaccinated and the positive effects on revenue was expected to dry-up and return to normalcy. Hence, the pandemic had a positive impact on the market players.
Market Value by Segment (2023)
Value (USD Mn)
Kits and Reagents
Analyzers
Software and Services
Companies
Key companies profiled in Immunoassays in R D Market
Profiles of 108 companies operating in the Immunoassays in R D Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Abcam plc
Abcam plc
Healthcare
Company Headquarters: Cambridge, UK Founded: 1998 Workforce: ~1,750 Company Working: Abcam plc is a global life sciences company that discovers, develops, and distributes high-quality biological reagents and tools for research, drug discovery, and diagnostics. It works across the industry to help life scientists complete their projects more quickly. It collaborates with life science organizations to develop novel binders for drug discovery, in-vitro diagnostics, and therapeutics. It supplies over 110,000 products to two-thirds of the world's life scientists to research protein targets, including antibodies, proteins, lysates, biochemicals, kits, and assays. It has thirteen locations globally and operates in over 130 countries worldwide. It manufactures its products in specialized facilities and sources them from over four hundred partners worldwide.
Revenue$0.3B
Employees1,750
Market CapN/A
Founded1997
Cambridge, UK
Sysmex Cor
Sysmex Corporation
Healthcare
Company Headquarters: Kobe, Japan Founded: 1968 Workforce: ~ 8,715 Company Working: Sysmex Corporation (Sysmex) develops, manufactures, sells, and exports/imports diagnostic instruments, reagents, and related software. The company provides products, services, and support to customers in more than 190 countries. Its key customers include national and other public hospitals, private hospitals, universities, research institutes, other medical institutions. Sysmex operates in the domain of healthcare testing, which involves examining blood, urine, and other samples. The company's business is in the domain of in vitro diagnostics (IVD), which is essential to the diagnosis and treatment of diseases. The company operates through various subsidiaries in different parts of the world, including the Americas, EMEA, and Asia-Pacific.
Revenue$2.7B
Employees8,715
Market CapN/A
Founded1967
Kobe, Japan
bioMérieux
bioMérieux
Healthcare
Company Headquarters: France Founded: 1963 Workforce: ~10,400 Company Working: BioMérieux is engaged in developing in-vitro diagnostics and microbiology testing services for the treatment of various infectious diseases. The company offers clinical diagnostics & industrial microbiology products and researches and develops solutions to treat diseases, such as sepsis, infections, cancer, cardiovascular diseases. It also develops solutions for biomarkers, biopharmaceutical control, and food safety. The firm operates through four major business segments, including microbiology, immunoassays, molecular biology, and industrial applications. The firm has a presence in more than 160 countries across the globe.
Revenue$3.4B
Employees10,400
Market CapN/A
Founded1962
France
Thermo Fis
Thermo Fisher Scientific
Healthcare
Company Headquarters: Massachusetts, US Founded: 2006 Workforce: ~70,000+ Company Working: Thermo Fisher Scientific specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, specialty diagnostics, and others. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the productivity of the laboratory. It has five premier brands, namely, Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services through which it offers an unmatched combination of innovative technologies, purchasing convenience and comprehensive services.
Revenue$18.3B
Employees70,000
Market CapN/A
Founded2005
Massachusetts, US
Abbott
Abbott
Healthcare
Company Headquarters: Illinois, US Founded: 1888 Workforce: ~115,000 Company Working: Abbott discovers, develops, manufactures, and sells healthcare products across the globe. The company operates through four reportable segments, namely, established pharmaceutical products, diagnostic products, nutritional products, and medical devices. The established pharmaceutical products segment offers a broad range of branded and generic pharmaceutical products. This segment focuses on emerging markets, including India, Brazil, Russia, and China. The nutritional products segment sells and distributes adult & pediatric nutritional products. The diagnostic products segment offers diagnostic tests and instruments for blood banks, hospitals, and commercial laboratories. Moreover, the medical devices segment offers devices for various treatments, including cardiac arrhythmias & heart failure, vascular, neuromodulation, structural heart, and diabetes care. Furthermore, Abbott sells its products to customers in more than 160 countries.
Revenue$20.4B
Employees115,000
Market CapN/A
Founded1887
Illinois, US
Danaher
Danaher
Healthcare
Company Headquarters: Washington, D.C., US Founded: 1969 Workforce: ~71,000 Company Working: Danaher designs, manufactures, and markets professional, medical, industrial, and commercial products and services all over the world. The company has five business segments, namely, life sciences, diagnostics, dental, water quality, and product identification. Its life sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. It also offers dental implant systems, high-precision individualized prosthetics, and CAD/CAM systems under the brand name Nobel Biocare. The company operates through more than 20 subsidiaries in the global market.
Revenue$16.9B
Employees71,000
Market CapN/A
Founded1968
Washington, D.C., US
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Immunoassays in R D Market
Starting from
$4,950